NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $14.49, for a total value of $6,692,916.51. Following the completion of the transaction, the insider now directly owns 3,542,068 shares in the company, valued at $51,324,565.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
NeuroPace Stock Performance
NASDAQ NPCE opened at $13.75 on Thursday. The stock has a market cap of $361.41 million, a P/E ratio of -10.74 and a beta of 2.08. The company has a quick ratio of 5.02, a current ratio of 5.71 and a debt-to-equity ratio of 2.76. NeuroPace, Inc. has a twelve month low of $3.80 and a twelve month high of $18.15. The company’s 50-day simple moving average is $14.59 and its 200 day simple moving average is $11.34.
NeuroPace (NASDAQ:NPCE – Get Free Report) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.10. The company had revenue of $18.01 million for the quarter, compared to analyst estimates of $17.74 million. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. As a group, research analysts forecast that NeuroPace, Inc. will post -1.14 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Report on NeuroPace
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Kent Lake Capital LLC grew its holdings in shares of NeuroPace by 285.0% in the 3rd quarter. Kent Lake Capital LLC now owns 574,417 shares of the company’s stock worth $5,589,000 after purchasing an additional 425,212 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of NeuroPace by 58.6% during the first quarter. Nantahala Capital Management LLC now owns 485,303 shares of the company’s stock worth $3,984,000 after buying an additional 179,397 shares in the last quarter. EAM Investors LLC acquired a new position in NeuroPace during the 3rd quarter worth about $1,378,000. Millennium Management LLC lifted its position in shares of NeuroPace by 18.2% during the fourth quarter. Millennium Management LLC now owns 691,899 shares of the company’s stock worth $1,031,000 after purchasing an additional 106,532 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of NeuroPace by 3.1% in the 4th quarter. Morgan Stanley now owns 2,188,593 shares of the company’s stock valued at $3,261,000 after buying an additional 64,990 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.
About NeuroPace
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
See Also
- Five stocks we like better than NeuroPace
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- United Airlines Soars on Earnings Beat
- Why Are Stock Sectors Important to Successful Investing?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Stock Average Calculator
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.